Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Status:
Terminated
Trial end date:
2018-12-19
Target enrollment:
Participant gender:
Summary
Independently, both lenalidomide and vorinostat have shown promising activity in pediatric
central nervous system (CNS) tumors. These are both agents that are not typically part of
first-line studies, although both agents are of serious interest and are currently in
clinical trials for further investigation. This study is to evaluate the combination of
lenalidomide and vorinostat in high grade or progressive central nervous system tumors in
children.